



(11) **EP 2 048 145 B9**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Claims DE
Claims EN
Claims FR

(51) Int Cl.:
C07D 409/12 ^(2006.01) **A61K 31/397** ^(2006.01)
A61P 1/16 ^(2006.01) **A61P 3/08** ^(2006.01)
A61P 35/00 ^(2006.01) **A61P 43/00** ^(2006.01)

(86) International application number:
PCT/JP2007/065165

(48) Corrigendum issued on:
04.05.2011 Bulletin 2011/18

(87) International publication number:
WO 2008/016107 (07.02.2008 Gazette 2008/06)

(45) Date of publication and mention
of the grant of the patent:
15.12.2010 Bulletin 2010/50

(21) Application number: **07791845.6**

(22) Date of filing: **02.08.2007**

(54) **PROTEIN KINASE C ACTIVITY ENHANCER CONTAINING ALKYL ETHER DERIVATIVE OR SALT THEREOF**

VERSTÄRKER DER AKTIVITÄT VON PROTEINKINASE C, ENTHALTEND EIN
ALKYLETHERDERIVAT ODER EIN SALZ DAVON

AMPLIFICATEUR DE L'ACTIVITÉ DE LA PROTÉINE KINASE C CONTENANT UN DÉRIVÉ D'ÉTHER
D'ALKYLE OU UN SEL DE CELUI-CI

(84) Designated Contracting States:
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE
SI SK TR**

• **TERASHIMA, Nobuo**
Toyama-shi
Toyama 930-8508 (JP)

(30) Priority: **04.08.2006 JP 2006212722**

(74) Representative: **Blodig, Wolfgang**
Wächtershäuser & Hartz
Weinstrasse 8
80333 München (DE)

(43) Date of publication of application:
15.04.2009 Bulletin 2009/16

(73) Proprietor: **Toyama Chemical Co., Ltd.**
Shinjuku-ku
Tokyo 160-0023 (JP)

(56) References cited:
WO-A1-01/55118 WO-A1-03/035647
JP-A- 09 507 846 JP-A- 2002 322 058
JP-A- 2005 527 512

(72) Inventors:
• **FUKUSHIMA, Tetsuo**
Toyama-shi
Toyama 930-8508 (JP)
• **TAKAGI, Akiko**
Toyama-shi
Toyama 930-8508 (JP)

• **TAKUMA K. ET AL.: 'T-588 inhibits astrocyte
apoptosis via mitogen-activated protein kinase
signal pathway' EUROPEAN JOURNAL OF
PHARMACOLOGY vol. 399, no. 1, 2000, pages 1
- 8, XP002906392**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 2 048 145 B9

Description

TECHNICAL FIELD

[0001] The present invention relates to a superior protein kinase C activity enhancer containing an alkyl ether derivative or a salt thereof.

BACKGROUND ART

[0002] In mammals, protein kinase C (hereinafter referred to as "PKC") is a family consisting of 12 isoforms, and it is known to be a serine-threonine kinase that takes part in signal transduction. In addition to this, PKC is known to be involved in regulating various cell functions such as synaptic transmission, ion flux activation, secretion, cell cycle control, differentiation, multiplication, tumorigenesis, metastasis, and apoptosis. Compounds having PKC activity enhancing effect (hereinafter referred to as "PKC activity enhancers") are known to have, for example, an ameliorating effect on glucose metabolism disorder in liver cirrhosis animal models (NON-PATENT DOCUMENT 1), and an antineoplastic effect (NON-PATENT DOCUMENT 2). PKC activity enhancers are drawing much attention as therapeutic agents against various diseases, for example, glucose metabolism disorders in liver cirrhosis patients, and neoplastic diseases such as tumors.

[0003] For example, leucine is known to be PKC activity enhancer (NON-PATENT DOCUMENT 3). Branched chain amino acids (leucine and isoleucine in particular), used in branched chain amino acid replacement therapy for liver cirrhosis patients, activate PKC through PI3 kinase, promote glucose uptake by skeletal muscles, and also ameliorate glucose metabolism disorders in the liver cirrhosis rat model (NON-PATENT DOCUMENT 1).

[0004] For example, bryostatin and gnidimacrin are also known as PKC activity enhancers. Bryostatin binds to PKC (NON-PATENT DOCUMENT 4), activates PKC isozymes in vitro (NON-PATENT DOCUMENT 5), and shows antineoplastic effect (NON-PATENT DOCUMENT 6).

[0005] The alkyl ether derivatives described in the present application have been reported to have nerve protective activity, nerve regenerative activity, and neurite outgrowth promoting activity (Patent document 1). However, it is not known so far that they enhance PKC activity.

[0006]

PATENT DOCUMENT 1: WO 03/035647

NON-PATENT DOCUMENT 1: Am. J. Physiol. Gastrointest. Liver. Physiol., 2005, Vol. 288, p. G1292-1300

NON-PATENT DOCUMENT 2: Curr. Cancer Drug Targets, 2004, Vol. 4, p. 125-146

NON-PATENT DOCUMENT 3: Biochem. Biophys.

Res. Commun., 2002, Vol. 299, No. 5, p. 693-696
NON-PATENT DOCUMENT 4: Biochem. Pharmacol., 1992, Vol. 43, No. 9, p. 2007-2014
NON-PATENT DOCUMENT 5: Mol. Pharmacol., 1994, Vol. 46, No. 2, p. 374-379
NON-PATENT DOCUMENT 6: Rev. Physiol. Biochem. Pharmacol., 2001, Vol. 142, p. 1-96

DISCLOSURE OF THE INVENTION

PROBLEMS TO BE SOLVED BY THE INVENTION

[0007] There is a demand for a superior PKC activity enhancer with fewer side effects.

MEANS FOR SOLVING THE PROBLEMS

[0008] Against the above background, the present inventors found that benzothiophene alkyl ether derivative defined in claim 1 and salts thereof show PKC activity enhancing effect and are therefore useful as PKC activity enhancers, and achieved the present invention.

[0009] The present invention provides the compound defined in the claim for use in the treatment or prevention of glucose metabolism disorder in liver cirrhosis patients or of neoplastic diseases such as tumors.

BEST MODE FOR CARRYING OUT THE INVENTION

[0010] The present invention is disclosed in more detail below.

The terms used in the present description have the meanings given below, unless specified otherwise.

[0011] The salt of the compound of the present invention may be a commonly known salt at a basic group such as an amino group, or salt at an acidic group such as a hydroxyl group.

Examples of salts at basic groups include salts of mineral acids such as hydrochloric acid, hydrobromic acid, nitric acid and sulfuric acid; salts of organic carboxylic acids such as formic acid, acetic acid, citric acid, oxalic acid, fumaric acid, maleic acid, succinic acid, malic acid, tartaric acid, aspartic acid, trichloroacetic acid and trifluoroacetic acid; and salts of sulfonic acids such as methane sulfonic acid, benzene sulfonic acid, p-toluene sulfonic acid, mesitylene sulfonic acid and naphthalene sulfonic acid.

[0012] Examples of salts at acidic groups include salts of alkali metals such as sodium and potassium; salts of alkali earth metals such as calcium and magnesium; ammonium salts; salts of nitrogen-containing organic bases such as trimethylamine, triethylamine, tributylamine, pyridine, N,N-dimethylaniline, N-methylpiperidine, N-methylmorpholine, diethylamine, dicyclohexylamine, procaine, dibenzylamine, N-benzyl-β-phenethylamine, 1-ephedrine and N,N'-dibenzylethylenediamine.

Among the salts described above, pharmacologically acceptable salts are preferable.

[0013] When the alkyl ether derivative defined in claim 1 and salts thereof have isomers such as optical isomers, geometric isomers and tautomers, the present invention covers all such isomers. The invention also covers hydrates, solvates, and all possible crystalline forms.

[0014] The compound is 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol (hereinafter referred to as "T-817") or a salt thereof is used in this invention, and the maleic acid salt of T-817 (hereinafter referred to as "T-817MA") is the most preferable.

[0015] The alkyl ether derivative defined in claim 1, or a salt thereof, has PKC activity enhancing effect, and drugs containing this alkyl ether derivative, or a salt thereof, are useful in treatment or prevention of diseases where the PKC activity enhancement is effective.

[0016] The alkyl ether derivative or a salt thereof used in the present invention may be prepared by a publicly known method, a suitable combination of the known methods, or by the method described in PATENT DOCUMENT 1.

[0017] The alkyl ether derivative or a salt thereof used in the present invention may be made into a drug product, such as an oral drug (tablet, capsule, powder, granule, fine granule, pill, suspension, emulsion, solution, syrup, etc.), injections, eye drops and the like, by compounding various drug additives such as excipients, binders, disintegrators, disintegration inhibitors, anti-caking and anti-sticking agents, lubricants, absorbing/adsorbing carriers, solvents, bulking agents, isotonic agents, solubilizers, emulsifiers, suspending agents, thickeners, coating agents, absorption enhancers, gelation/coagulation promoters, light stabilizers, preservatives, desiccants, emulsion/suspension/dispersion stabilizers, coloration preventing agents, deoxidizers/antioxidants, flavoring agents, coloring agents, whipping agents, antifoaming agents, soothing agents, antistatic agents and buffering/pH regulating agents.

The above-mentioned drug products are prepared by ordinary methods.

[0018] The solid oral drug products such as tablets, powders and granules, may be prepared by conventional methods, by adding drug additives for solid drug products, for example, excipients such as lactose, sucrose, sodium chloride, glucose, starch, calcium carbonate, kaolin, crystalline cellulose, anhydrous dibasic calcium phosphate, partially alpha starch, corn starch and alginic acid; binders such as simple syrup, glucose solution, starch solution, gelatin solution, polyvinyl alcohol, polyvinyl ether, polyvinylpyrrolidone, carboxymethylcellulose, shellac, methylcellulose, ethylcellulose, sodium alginate, gum arabic, hydroxypropylmethylcellulose, hydroxypropylcellulose, water and ethanol; disintegrators such as dry starch, alginic acid, agar powder, starch, cross-linked polyvinylpyrrolidone, cross-linked carboxymethylcellulose sodium, carboxymethylcellulose calcium and sodium starch glycolate; disintegration inhibitors such as stearyl alcohol, stearic acid, cocoa butter and hydrogenated oil; anti-caking/anti-sticking agents

such as aluminum silicate, calcium hydrogen phosphate, magnesium oxide, talc and anhydrous silicic acid; lubricants such as carnauba wax, light anhydrous silicic acid, aluminum silicate, magnesium silicate, hardened oil, hardened vegetable oil derivative, sesame oil, bleached beeswax, titanium oxide, dry aluminum hydroxide gel, stearic acid, calcium stearate, magnesium stearate, talc, calcium hydrogen phosphate, sodium lauryl sulfate and polyethylene glycol; absorption enhancers such as quaternary ammonium salts, sodium lauryl sulfate, urea and enzymes; absorption/adsorption carriers such as starch, lactose, kaolin, bentonite, anhydrous silicic acid, hydrated silicon dioxide, magnesium aluminometasilicate and colloidal silicic acid.

In the case of tablets, if needed, they may be made into ordinary coated tablets, such as sugarcoated tablets, gelatin-coated tablets, gastric-coated tablets, enteric-coated tablets, and watersoluble film-coated tablets.

Capsules are prepared by first mixing with the various above-listed drug products, and packing into hard gelatin capsules, soft capsules, and the like.

Aqueous or oil-based suspensions, solutions, syrups and elixirs may be also prepared, using various aforementioned additives for liquid drug products, for example, solvents, bulking agents, isotonic agents, solubilizers, emulsifiers, suspending agents and thickeners.

[0019] Injections may be prepared by a conventional method, using drug additives for liquid drug products, for example, diluents such as water, ethyl alcohol, Macrogol, propylene glycol, citric acid, acetic acid, phosphoric acid, lactic acid, sodium lactate, sulfuric acid and sodium hydroxide; pH regulators and buffering agents such as sodium citrate, sodium acetate and sodium phosphate; stabilizers such as sodium pyrosulfite, ethylenediamine tetraacetic acid, thioglycolic acid and thiolactic acid; isotonic agents such as common salt, glucose, mannitol and glycerol; solubilizers such as carboxymethylcellulose sodium, propylene glycol, sodium benzoate, benzyl benzoate, urethane, ethanolamine and glycerol; soothing agents such as calcium gluconate, chlorobutanol, glucose and benzyl alcohol; and local anesthetics.

[0020] Eye drops may be prepared by a conventional method, by suitably compounding with, for example, preservatives such as chlorobutanol, sodium dehydroacetate, benzalkonium chloride, cetylpyridinium chloride, phenethyl alcohol, methyl parahydroxybenzoate and benzethonium chloride; buffering agents such as borax, boric acid and potassium dihydrogen phosphate; thickeners such as methylcellulose, hydroxyethylcellulose, carboxymethylcellulose, hydroxypropylmethylcellulose, polyvinyl alcohol, carboxymethylcellulose sodium and chondroitin sulfate; solubilizers such as polysorbate 80 and polyoxyethylene hardened castor oil 60; stabilizers such as sodium edetate and sodium hydrogen sulfite; and isotonic agents such as sodium chloride, potassium chloride and glycerol.

[0021] There is no particular restriction on the method of administering the above-mentioned drug products; it

has to be decided, taking into consideration the dosage form, the age, sex and other conditions of the patient, and the severity of the symptoms.

The dose of the active ingredient of the drug product of the present invention is decided suitably, according to the dose regimen, age and sex of the patient, pattern of the disease, and other conditions. However, usually, 0.1 to 500 mg/day may be given to an adult, at once or in a few administrations.

EXAMPLES

[0022] The present invention is described below, with the help of some experimental examples and formulation examples. However, these examples do not in any way limit the scope of the invention.

In these experiments, T-817MA was used as the test substance.

Experimental Example 1 PKC activity enhancing effect in cultured cells

[0023] The PKC activity was determined, according to the method of Etcheberrigaray et al. (Proceedings of the National Academy of Sciences of the United States of America, 2004, Vol. 101, No. 30, p. 11141-11146), as applicable. At the time of activation, PKC migrates from the cytoplasm to membranes. The PKC level in the membrane fraction over that in the cytosol fraction was taken as the index of PKC activation. In this experiment, the activity of PKC ϵ , a known isoform of PKC, was measured. Cultured cells were prepared following the method of Hirata et al. (J. Pharmacol. Exp. Ther., 2005, Vol. 314, No. 1, p. 252-259).

The cerebral cortex was removed from 18-day fetuses of Wistar/ST rats, and incubated in phosphate-buffered physiological saline (hereinafter referred to as "PBS") containing 0.25% trypsin and 40 Kunitz units/mL DNase I, for 20 minutes at 37°C. After that, an equal mixture of fetal bovine serum (manufactured by JRH Co.) and Dulbecco's Modified Eagle Medium (hereinafter referred to as "DMEM") was added, and cells in the suspension were dispersed by pipetting. This suspension was filtered through a lens paper, centrifuged for 5 minutes at 1000 rpm, and the cells dispersed again by pipetting in DMEM containing 10% fetal bovine serum. The cells were then inoculated at a density of 4×10^5 cells/mL in 5 mL of medium in a 60 mm tissue culture dish that had been coated with poly-L lysine, and cultured. On Day 2 from the start of the culturing, 50 μ L of 1 mmol/L AraC solution was added to each dish. 24 hours later, the medium was changed to 5 mL of DMEM containing 10% fetal bovine serum.

[0024] On Day 8 from the start of the culturing, T-817MA was added to the cells to a final concentration of 0.1 μ mol/L, in terms of T-817. After this addition, the cells were washed with PBS at 0 (untreated), 1, 2 and 4 hours. Then, using a cell scraper, the cells were gathered into

an extraction buffer (20 mmol/L Tris-HCl, pH 7.5, 2 mmol/L EDTA, 2 mmol/L EGTA, 5 mmol/L DTT, 0.32 mol/L sucrose, and 1/100 volume of protease inhibitor cocktail (manufactured by SIGMA)). The cell extract was ultrasonicated and the supernatant obtained after centrifuging for 20 minutes at $12000 \times g$ was designated as the cytosol fraction. The extraction buffer containing 1% Triton X-100 was added to the pellet. After ultrasonication, it was left standing on ice for 45 minutes. It was again centrifuged for 20 minutes at $12000 \times g$, and the supernatant obtained was designated as the membrane fraction. The protein concentration in the cytosol fraction and the membrane fraction was measured, and the protein content in each sample was adjusted to a certain constant level with the extraction buffer or the extraction buffer containing Triton X-100. These samples were then diluted with electrophoresis buffer containing mercaptoethanol (manufactured by Wako Pure Chemical Industries Ltd.) and SDS-PAGE (40 mA, 30 minutes) was carried on 10% polyacrylamide gel. After completing the SDS-PAGE, the protein on the gel was transferred to a PVDF membrane (150 mA, 90 minutes). The membrane was shaken for 60 minutes in PBST (PBS containing 0.1% Tween 20) containing 5% skim milk. After that, the membrane was immersed in PBS containing anti-mouse PKC ϵ antibody (manufactured by BD Transduction Laboratories, diluted 500 times) and left standing for 90 minutes. Then, after washing the membrane with PBST, it was shaken for 90 minutes in PBST containing HRP-labeled anti-mouse IgG antibody (manufactured by GE Healthcare Bio-Sciences, diluted 2500 times). Then, after washing with PBST, the membrane was treated with ECL plus reagent (manufactured by GE Healthcare Bio-Sciences) and the luminescence was detected by a Lumino Image Analyzer. The PKC ϵ bands of the samples were compared. The results are shown in Fig. 1.

[0025] The PKC ϵ was seen to have migrated from the cytoplasm to membranes in 2 hours and 4 hours after the cells were treated with T-817MA. The migration of the PKC from the cytoplasm to the membrane may be taken as an index of activation. Therefore, it was demonstrated that T-817MA had PKC ϵ activity enhancing effect.

Formulation Example 1

[0026] A mixture of 50 mg T-817MA, 20 mg lactose, 25 mg corn starch, and 40 mg Avicel PH101 (manufactured by Asahi Kasei Corporation) was blended using a 5% aqueous solution of polyvinylpyrrolidone K30. After drying the mixture at 60°C, a mixture of 10 mg of Kollidon CL (manufactured by BASF Co., Ltd.), 10 mg Avicel PH302 (manufactured by Asahi Kasei Corporation), 18 mg light anhydrous silicic acid, and 2 mg magnesium stearate was mixed with it, and tableted into circular tablets of diameter 7 mm, each weighing 175 mg and containing 50 mg of T-817MA.

Formulation Example 2

[0027] A mixture of 50 mg T-817MA, 20 mg lactose and 53 mg corn starch was blended using a 5% aqueous solution of polyvinylpyrrolidone K30 and dried at 60°C. After that a mixture of 7 mg Kollidon CL (manufactured by BASF Co., Ltd.), 18 mg Avicel PH302 (manufactured by Asahi Kasei Corporation), and 2 mg of magnesium stearate was mixed with it. 150 mg of this mixture was filled per capsule in No. 4 gelatin capsules to prepare drug capsules.

BRIEF DESCRIPTION OF THE DRAWING

[0028] Fig. 1 is the result of western blotting in the experiment where PKC activity in cultured cells was measured.

INDUSTRIAL APPLICABILITY

[0029] The alkyl ether derivative, or salt thereof, of the present invention shows PKC activity enhancing effect and is useful in treatment or prevention of various diseases where PKC is involved, for example, glucose metabolism disorder in liver cirrhosis patients, and neoplastic diseases such as tumors.

Claims

1. 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof for use in the treatment or prevention of glucose metabolism disorder in liver cirrhosis patients or of neoplastic diseases.


Patentansprüche

1. 1-(3-(2-(1-Benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol oder ein Salz davon zur Verwendung bei der Behandlung oder zur Vorbeugung von Störungen des Glukosestoffwechsels bei einem Patienten mit Leberzirrhose oder bei neoplastischen Erkrankungen.

Revendications

1. 1-(3-(2-(1-benzothiophèn-5-yl)éthoxy)propyl)azétidin-3-ol ou sel de celui-ci pour utilisation dans le traitement ou la prévention de maladies néoplasiques ou de troubles du métabolisme du glucose chez des patients atteints de cirrhose hépatique.

FIG. 1



REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- WO 03035647 A [0006]

Non-patent literature cited in the description

- | | |
|---|---|
| <ul style="list-style-type: none"> • <i>Am. J. Physiol. Gastrointest. Liver. Physiol.</i>, 2005, vol. 288, G1292-1300 [0006] • <i>Curr. Cancer Drug Targets</i>, 2004, vol. 4, 125-146 [0006] • <i>Biochem. Biophys. Res. Commun.</i>, 2002, vol. 299 (5), 693-696 [0006] • <i>Biochem. Pharmacol.</i>, 1992, vol. 43 (9), 2007-2014 [0006] | <ul style="list-style-type: none"> • <i>Mol. Pharmacol.</i>, 1994, vol. 46 (2), 374-379 [0006] • <i>Rev. Physiol. Biochem. Pharmacol.</i>, 2001, vol. 142, 1-96 [0006] • Etcheberrigaray et al. <i>Proceedings of the National Academy of Sciences of the United States of America</i>, 2004, vol. 101 (30), 11141-11146 [0023] • Hirata et al. <i>J. Pharmacol. Exp. Ther.</i>, 2005, vol. 314 (1), 252-259 [0023] |
|---|---|